Eli Lilly Sues Vendors for Selling Unauthorized Tirzepatide Products

The pharmaceutical company targets medical spas and online sellers for marketing unapproved versions of its weight-loss drug, Zepbound.

Eli Lilly has filed lawsuits against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine for allegedly selling unauthorized tirzepatide products.
The lawsuits claim these vendors falsely advertised products as containing tirzepatide, despite lacking FDA approval for such formulations.
Lilly has emphasized that the legal action is not related to the recent resolution of the tirzepatide supply shortage.
The company seeks court orders to stop the sale of these products and is pursuing unspecified monetary damages.
The FDA has allowed compounding pharmacies to continue providing tirzepatide while reconsidering its drug shortage status.